As we predicted just a couple of weeks ago, on Friday the US Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC), based on the results of the Phase III PROSPER trial, which were initially reported at the beginning of the year at the […]
↧
